Camille M Le Gall

7PUBLICATIONS
48CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Supramolecular chemistryNanofabrication, growth and self assemblyInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 16, 2025
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy.

Xin Liu, Camille Le Gall, Ryan K Alexander

|Apr 09, 2025
Site-directed multivalent conjugation of antibodies to ubiquitinated payloads.

Angela F El Hebieshy, Zacharias Wijfjes, Camille M Le Gall

|Aug 16, 2024
Bi-specific antibody engagers for cancer immunotherapy.

Hidde Ploegh, Xin Liu, Camille Le Gall

|Jun 03, 2024
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire.

Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski

|Sep 18, 2023
Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors.

Zacharias Wijfjes, Floris J van Dalen, Camille M Le Gall

|Apr 16, 2022
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.

Camille Le Gall, Anna Cammarata, Lukas de Haas

Pageof 2

Frequent Collaborators

4 joint publications

Martijn Verdoes

3 joint publications

Zacharias Wijfjes

3 joint publications

Carl G Figdor

2 joint publications

Iván Ramos-Tomillero